Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Blood (2017) 130 (Supplement 1): 1509.

https://doi.org/10.1182/blood.V130.Suppl_1.1509.1509

Published: 2017

Journal Articles

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Youn H Kim, MD, Sean Whittaker, MB, ChB, FRCP, MD, Steven M Horwitz, MD, Madeleine Duvic, MD, Reinhard Dummer, MD, Julia J Scarisbrick, MBChB FRCP MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD PhD, Pascal Wolter, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Erin Zagadailov, PharmD, MS, William L Trepicchio, PhD, Yi Liu, PhD, Meredith Little, MPH, H Miles Prince, MD

Blood (2016) 128 (22): 182.

https://doi.org/10.1182/blood.V128.22.182.182

Published: 2016

Journal Articles

Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma

Madeleine Duvic, MD, Steven M Horwitz, MD, Youn H Kim, MD, Pier Luigi Zinzani, Gajanan Bhat, PhD, Pankaj Sharma, Sue Yancik

Blood (2015) 126 (23): 2677.

https://doi.org/10.1182/blood.V126.23.2677.2677

Published: 2015

Journal Articles

High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma

Kimon V. Argyropoulos, MD, Steven M Horwitz, MD, Franck Rapaport, PhD, Enrico Velardi, PhD, Patricia Myskowski, MD, Christiane Querfeld, Melissa Pulitzer, MD, Ahmet Dogan, MD PhD, Meighan Gallagher, MA, Nicholas D. Socci, PhD, Ross L. Levine, MD, Minal Patel, BA, Natasha Galasso, Marcel van den Brink, MD PhD, Lia Palomba, MD

Blood (2015) 126 (23): 1485.

https://doi.org/10.1182/blood.V126.23.1485.1485

Published: 2015

Journal Articles

A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders

Thirunavukkarasu Velusamy, Mark J. Kiel, Anagh A. Sahasrabuddhe, Delphine Rolland, Catherine A. Dixon, Nathanael G. Bailey, Bryan L. Betz, Noah A. Brown, Alexandra C. Hristov, Ryan A. Wilcox, Roberto N. Miranda, L. Jeffrey Medeiros, Yoon K. Jeon, Kedar V. Inamdar, Megan S. Lim, Kojo S. J. Elenitoba-Johnson

Blood (2014) 124 (25): 3768–3771.

https://doi.org/10.1182/blood-2014-07-588434

Published: 2014

Includes: Supplemental data

Journal Articles

Novel Gene Translocations Involving TYK2 in Cutaneous CD30-Positive Lymphoproliferative Disorders

Thirunavukkarasu Velusamy, PhD, Mark J. Kiel, MD PhD, Anagh A Sahasrabuddhe, PhD, Delphine C.M. Rolland, PharmD, PhD, Catherine A Dixon, PhD, Nathanael G. Bailey, MD, Bryan L Betz, PhD, Noah A. Brown, MD, Alexandra C Hristov, MD, Ryan A. Wilcox, MD PhD, Roberto N. Miranda, MD, L. Jeffrey Medeiros, MD, Yoon K Jeon, MD, Megan S Lim, MD PhD, Kojo S.J. Elenitoba-Johnson, MD

Blood (2014) 124 (21): 3032.

https://doi.org/10.1182/blood.V124.21.3032.3032

Published: 2014

Journal Articles

Primary Cutaneous Anaplastic Large Cell Lymphoma: The British Columbia Cancer Agency Experience

Greg Hapgood, BMBS, Laurie H. Sehn, MDMPH, Diego Villa, MDMPH, Richard Klasa, MD, Alina S. Gerrie, MD MPH, Randy D. Gascoyne, MD, Christina Parsons, MD, James Morris, MD, Tom Pickles, MD, Joseph M. Connors, MD, Kerry J. Savage, MDMSc

Blood (2014) 124 (21): 3076.

https://doi.org/10.1182/blood.V124.21.3076.3076

Published: 2014

Journal Articles

Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial.

Steven M. Horwitz, MD, Madeleine Duvic, MD, Youn Kim, MD, Jasmine M Zain, MD, Mary Jo Lechowicz, MD, Patricia Myskowski, MD, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 919.

https://doi.org/10.1182/blood.V114.22.919.919

Published: 2009

Journal Articles

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRACP, Mark Kirschbaum, MD, John P Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Elaine Jaffe, MD, Susan Bates, MD

Blood (2008) 112 (11): 1567.

https://doi.org/10.1182/blood.V112.11.1567.1567

Published: 2008

Journal Articles

Cutaneous Lymphocyte Antigen and TRAF-1 Are Useful in Differentiating Lymphomatoid Papulosis, Cutaneous ALCL and Systemic ALCL.

Dorna Rezania, MD, Elizabeth Sagatys, MD, L. Frank Glass, MD, Marshall E. Kadin, MD, Hernani Cualing, MD

Blood (2008) 112 (11): 1785.

https://doi.org/10.1182/blood.V112.11.1785.1785

Published: 2008

Journal Articles

HLA-Identical Allogeneic Stem Cell Transplantation (alloSCT) for Patients with Primary Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT-LWP).

Rafael Duarte, Carme Canals, Francesco Onida, Eduardo Olavarria, William Arcese, Augustin Ferrant, Franco Narni, Andrea Bacigalupo, Donald Bunjes, Jacob Rowe, Giorgio Lambertenghi, Norbert Schmitz, Anna Sureda

Blood (2008) 112 (11): 1132.

https://doi.org/10.1182/blood.V112.11.1132.1132

Published: 2008

Journal Articles

Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Clinical and Molecular Characterization of a Subset with Worse Outcome.

Denise Woo, MD, Chris Jones, MD, Monique Vanoli-Storz, MD, Sabine Kohler, MD, Sunil Reddy, MD, Ranjana Advani, MD, Richard Hoppe, MD, Youn Kim, MD

Blood (2007) 110 (11): 3573.

https://doi.org/10.1182/blood.V110.11.3573.3573

Published: 2007

Journal Articles

A Phase I Trial of Subcutaneous (SQ) Dose-Escalated Alemtuzumab in Patients with T-Cell Lymphoproliferative Disorders (T-LPD).

Pierluigi Porcu, MD, Robert A. Baiocchi, MD, Thomas S. Lin, MD, PhD, Kristie A. Blum, MD, Patricia Curtis, RN, Grever R. Michael, MD, John C. Byrd, MD

Blood (2007) 110 (11): 3417.

https://doi.org/10.1182/blood.V110.11.3417.3417

Published: 2007

Journal Articles

Recurrence Patterns of Non-Mycosis Fungoides Cutaneous Lymphoma Following Various Treatment Modalities.

Michael E. Confer, Jonathan D. Tward, M.D. Ph.D., Sherrie L. Perkins, M.D., Glen M. Bowen, M.D., Robert J. Lee, M.D., Martha J. Glenn, M.D., David K. Gaffney, M.D. Ph.D.

Blood (2006) 108 (11): 4676.

https://doi.org/10.1182/blood.V108.11.4676.4676

Published: 2006

Journal Articles

Treatment of Systemic Primary Cutaneous Anaplastic Large Cell Lymphoma with High-Dose Methotrexate and Leucovorin Rescue.

Reema Batra, MD, James Boyer, MD, Thomas O’Connor, MD, Imad Tabbara, MD

Blood (2005) 106 (11): 4756.

https://doi.org/10.1182/blood.V106.11.4756.4756

Published: 2005

NARROW

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma

High-Depth, Targeted, Next Generation Sequencing Identifies Novel Genetic Alterations in Cutaneous T-Cell Lymphoma

A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders

Novel Gene Translocations Involving TYK2 in Cutaneous CD30-Positive Lymphoproliferative Disorders

Primary Cutaneous Anaplastic Large Cell Lymphoma: The British Columbia Cancer Agency Experience

Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial.

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Cutaneous Lymphocyte Antigen and TRAF-1 Are Useful in Differentiating Lymphomatoid Papulosis, Cutaneous ALCL and Systemic ALCL.

HLA-Identical Allogeneic Stem Cell Transplantation (alloSCT) for Patients with Primary Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT-LWP).

Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Clinical and Molecular Characterization of a Subset with Worse Outcome.

A Phase I Trial of Subcutaneous (SQ) Dose-Escalated Alemtuzumab in Patients with T-Cell Lymphoproliferative Disorders (T-LPD).

Recurrence Patterns of Non-Mycosis Fungoides Cutaneous Lymphoma Following Various Treatment Modalities.

Treatment of Systemic Primary Cutaneous Anaplastic Large Cell Lymphoma with High-Dose Methotrexate and Leucovorin Rescue.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only